Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
American Eagle Outfitters, Inc. stock logo
AEO
American Eagle Outfitters
$10.07
+0.4%
$10.58
$9.27
$22.83
$1.74B1.455.79 million shs4.58 million shs
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$47.68
+1.4%
$47.65
$39.71
$63.33
$97.03B0.3612.86 million shs11.73 million shs
Calavo Growers, Inc. stock logo
CVGW
Calavo Growers
$26.67
-1.0%
$26.70
$20.30
$30.02
$475.79M0.39244,839 shs203,904 shs
Okta, Inc. stock logo
OKTA
Okta
$99.15
+1.7%
$108.74
$70.56
$127.57
$17.36B0.823.09 million shs3.31 million shs
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
$76.01
$75.83
$23.77
$82.20
$3.81B-0.181.14 million shs4,322 shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
American Eagle Outfitters, Inc. stock logo
AEO
American Eagle Outfitters
+1.21%-1.67%-1.09%-10.93%-49.45%
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
+1.23%-0.88%-2.79%-12.51%+17.68%
Calavo Growers, Inc. stock logo
CVGW
Calavo Growers
+0.90%-1.93%-2.64%+17.74%+20.64%
Okta, Inc. stock logo
OKTA
Okta
+0.13%-1.04%-7.19%-4.13%-0.53%
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
American Eagle Outfitters, Inc. stock logo
AEO
American Eagle Outfitters
4.6425 of 5 stars
4.02.03.30.52.81.71.9
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
4.9251 of 5 stars
3.23.04.24.03.53.31.3
Calavo Growers, Inc. stock logo
CVGW
Calavo Growers
3.7496 of 5 stars
3.52.01.70.01.43.31.9
Okta, Inc. stock logo
OKTA
Okta
4.5663 of 5 stars
3.23.00.03.72.72.51.9
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
American Eagle Outfitters, Inc. stock logo
AEO
American Eagle Outfitters
2.00
Hold$14.7045.98% Upside
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
2.32
Hold$58.0021.64% Upside
Calavo Growers, Inc. stock logo
CVGW
Calavo Growers
3.00
Buy$35.0031.23% Upside
Okta, Inc. stock logo
OKTA
Okta
2.46
Hold$119.4420.47% Upside
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CVGW, OKTA, AEO, TPTX, and BMY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/7/2025
Okta, Inc. stock logo
OKTA
Okta
Arete Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong Sell$83.00
7/7/2025
Okta, Inc. stock logo
OKTA
Okta
Arete
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSell$83.00
6/6/2025
American Eagle Outfitters, Inc. stock logo
AEO
American Eagle Outfitters
Cfra Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeModerate Buy ➝ Hold
6/2/2025
American Eagle Outfitters, Inc. stock logo
AEO
American Eagle Outfitters
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetEqual Weight ➝ Equal Weight$11.00 ➝ $10.00
5/30/2025
American Eagle Outfitters, Inc. stock logo
AEO
American Eagle Outfitters
Telsey Advisory Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Perform ➝ Hold$12.00
5/28/2025
Okta, Inc. stock logo
OKTA
Okta
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$119.00
5/28/2025
Okta, Inc. stock logo
OKTA
Okta
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$123.00 ➝ $137.00
5/28/2025
Okta, Inc. stock logo
OKTA
Okta
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$135.00 ➝ $130.00
5/28/2025
Okta, Inc. stock logo
OKTA
Okta
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetMarket Perform ➝ Market Perform$135.00 ➝ $132.00
5/28/2025
Okta, Inc. stock logo
OKTA
Okta
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$109.00 ➝ $115.00
5/28/2025
Okta, Inc. stock logo
OKTA
Okta
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$120.00 ➝ $130.00
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
American Eagle Outfitters, Inc. stock logo
AEO
American Eagle Outfitters
$5.33B0.33$3.01 per share3.34$9.20 per share1.09
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$48.30B2.01$6.04 per share7.90$8.08 per share5.90
Calavo Growers, Inc. stock logo
CVGW
Calavo Growers
$661.54M0.72$1.66 per share16.08$11.34 per share2.35
Okta, Inc. stock logo
OKTA
Okta
$2.61B6.65$1.79 per share55.42$36.89 per share2.69
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
$30.83M123.46N/AN/A$15.84 per share4.80
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
American Eagle Outfitters, Inc. stock logo
AEO
American Eagle Outfitters
$329.38M$0.9810.285.59N/A3.73%13.34%5.99%8/27/2025 (Estimated)
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
-$8.95B$2.6717.867.831.3811.38%87.62%15.98%7/31/2025 (Estimated)
Calavo Growers, Inc. stock logo
CVGW
Calavo Growers
-$1.08M$0.5845.9811.50N/A1.50%11.79%7.38%9/8/2025 (Estimated)
Okta, Inc. stock logo
OKTA
Okta
$28M$0.63157.38159.924.714.85%2.79%1.92%8/27/2025 (Estimated)
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
-$236.55M-$6.90N/AN/AN/AN/A-37.45%-35.62%N/A

Latest CVGW, OKTA, AEO, TPTX, and BMY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/31/2025Q2 2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$1.53N/AN/AN/A$11.32 billionN/A
6/9/2025Q2 2025
Calavo Growers, Inc. stock logo
CVGW
Calavo Growers
$0.5330$0.40-$0.1330$0.38$192.75 million$190.55 million
5/29/2025Q1 2026
American Eagle Outfitters, Inc. stock logo
AEO
American Eagle Outfitters
-$0.25-$0.29-$0.04-$0.36$1.08 billion$1.09 billion
5/27/2025Q1 2026
Okta, Inc. stock logo
OKTA
Okta
$0.77$0.86+$0.09$0.35$680.14 million$688.00 million
4/24/2025Q1 2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$1.50$1.80+$0.30$1.21$10.77 billion$11.20 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
American Eagle Outfitters, Inc. stock logo
AEO
American Eagle Outfitters
$0.504.97%N/A51.02%2 Years
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$2.485.20%N/A92.88%17 Years
Calavo Growers, Inc. stock logo
CVGW
Calavo Growers
$0.803.00%N/A137.93%1 Years
Okta, Inc. stock logo
OKTA
Okta
N/AN/AN/AN/AN/A
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
N/AN/AN/AN/AN/A

Latest CVGW, OKTA, AEO, TPTX, and BMY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/17/2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
quarterly$0.625.25%7/3/20257/3/20258/1/2025
6/3/2025
Calavo Growers, Inc. stock logo
CVGW
Calavo Growers
quarterly$0.203.4%6/30/20256/30/20257/30/2025
6/4/2025
American Eagle Outfitters, Inc. stock logo
AEO
American Eagle Outfitters
quarterly$0.12504.87%7/11/20257/11/20257/25/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
American Eagle Outfitters, Inc. stock logo
AEO
American Eagle Outfitters
0.07
1.38
0.56
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
2.65
1.28
1.17
Calavo Growers, Inc. stock logo
CVGW
Calavo Growers
0.02
2.00
1.54
Okta, Inc. stock logo
OKTA
Okta
0.05
1.47
1.47
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
N/A
16.83
16.83

Institutional Ownership

CompanyInstitutional Ownership
American Eagle Outfitters, Inc. stock logo
AEO
American Eagle Outfitters
97.33%
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
76.41%
Calavo Growers, Inc. stock logo
CVGW
Calavo Growers
81.30%
Okta, Inc. stock logo
OKTA
Okta
86.64%
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
90.33%
CompanyEmployeesShares OutstandingFree FloatOptionable
American Eagle Outfitters, Inc. stock logo
AEO
American Eagle Outfitters
44,000173.27 million158.19 millionOptionable
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
34,1002.04 billion2.03 billionOptionable
Calavo Growers, Inc. stock logo
CVGW
Calavo Growers
2,10617.84 million16.55 millionOptionable
Okta, Inc. stock logo
OKTA
Okta
5,914175.07 million165.13 millionOptionable
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
25050.07 million45.77 millionNot Optionable

Recent News About These Companies

Turning Point of Tampa Now In-Network with Blue Cross Blue Shield Insurance
Glass System in Turning Point Residence
Turning Point Brands Inc.
Alzheimer’s: A Turning Point?
Turning Point Brands Inc (TPB)
Cormorant Asset Management, LP's Net Worth
Solving quadratic equations - Edexcel
BMS bet looking good as Augtyro approved in ROS1-positive NSCLC
A Turning Point for Japan-US Climate Cooperation?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
American Eagle Outfitters stock logo

American Eagle Outfitters NYSE:AEO

$10.07 +0.04 (+0.40%)
Closing price 03:57 PM Eastern
Extended Trading
$10.06 -0.01 (-0.10%)
As of 05:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

American Eagle Outfitters, Inc. operates as a multi-brand specialty retailer in the United States and internationally. The company provides jeans, apparel and accessories, and personal care products for women and men under the American Eagle brand; and intimates, apparel, activewear, and swim collections under the Aerie and OFFLINE by Aerie brands. It also offers menswear products under the Todd Snyder New York brand; and fashion clothing and accessories under the Unsubscribed brand. The company sells its products through own and licensed retail stores; concession-based shops-within-shops; and digital channels, such as www.ae.com, www.aerie.com, www.toddsnyder.com, and www.unsubscribed.com. American Eagle Outfitters, Inc. was founded in 1977 and is headquartered in Pittsburgh, Pennsylvania.

Bristol Myers Squibb stock logo

Bristol Myers Squibb NYSE:BMY

$47.68 +0.64 (+1.36%)
Closing price 03:57 PM Eastern
Extended Trading
$47.67 -0.01 (-0.02%)
As of 06:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Calavo Growers stock logo

Calavo Growers NASDAQ:CVGW

$26.67 -0.28 (-1.04%)
Closing price 04:00 PM Eastern
Extended Trading
$26.67 0.00 (0.00%)
As of 05:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Calavo Growers, Inc. markets and distributes avocados, prepared avocados, and other perishable foods to retail grocery and foodservice customers, club stores, mass merchandisers, food distributors, and wholesale customers worldwide. It operates through Grown and Prepared segments. The Grown segment distributes tomatoes and papayas; and procures avocados grown in California, Mexico, Peru, and Colombia. The Prepared segment is involved in the distribution of prepared avocado products, salsa, fresh-cut fruit and vegetables, fresh prepared entrees salads, wraps, sandwiches, parfaits, and fresh snacking products, as well as ready-to-heat entrees, other hot bars and various deli items, meals kit components, and salad kits. It offers its products under the Calavo brands and related logos; and Avo Fresco, Bueno, Avo Fresco, Bueno, Calavo Gold, Celebrate the Taste, El Dorado, Taste of Paradise, The First Name in Avocados, The Family of Fresh, ProRipeVIP, RIPE NOW!, Renaissance Food Group, Garden Highway Fresh Cut, Garden Highway, and Garden Highway Chef Essentials trademarks. Calavo Growers, Inc. was founded in 1924 and is headquartered in Santa Paula, California.

Okta stock logo

Okta NASDAQ:OKTA

$99.15 +1.62 (+1.66%)
Closing price 04:00 PM Eastern
Extended Trading
$99.22 +0.07 (+0.08%)
As of 06:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Okta, Inc. operates as an identity partner in the United States and internationally. The company offers Okta's suite of products and services used to manage and secure identities, such as Single Sign-On that enables users to access applications in the cloud or on-premises from various devices; Adaptive Multi-Factor Authentication provides a layer of security for cloud, mobile, web applications, and data; API Access Management enables organizations to secure APIs; Access Gateway enables organizations to extend Workforce Identity Cloud; and Okta Device Access enables end users to securely log in to devices with Okta credentials. It also provides Universal Directory, a cloud-based system of record to store and secure user, application, and device profiles for an organization; Lifecycle Management enables IT organizations or developers to manage a user's identity throughout its lifecycle; Okta Identity Governance provides identity access management and identity governance solutions; Advanced Server Access offers access management to secure cloud infrastructure; Okta Privileged Access enables organizations to reduce risk with unified access and governance management for on-premises and cloud resources; and Okta Workforce Identity Workflows. In addition, the company offers Universal Login, which allows customers to provide login experience across different applications and devices; and Attack Protection, a suite of security capabilities that protects customers from different types of malicious traffic. Further, it provides Adaptive Multi-Factor Authentication, Passwordless, Machine to Machine, Private Cloud, Organizations, Actions and Extensibility, and Enterprise Connections. The company sells its products directly to customers through sales force and channel partners. The company was formerly known as Saasure, Inc. Okta, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Turning Point Therapeutics stock logo

Turning Point Therapeutics NASDAQ:TPTX

Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California.